Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy.

TitleAssociation between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy.
Publication TypeJournal Article
Year of Publication2010
AuthorsBrown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA
JournalDiabetes Care
Volume33
Issue10
Pagination2244-9
Date Published2010 Oct
ISSN1935-5548
KeywordsAdult, Anti-Retroviral Agents, C-Reactive Protein, Case-Control Studies, Diabetes Mellitus, Type 2, Enzyme-Linked Immunosorbent Assay, Female, HIV Infections, Humans, Inflammation, Interleukin-6, Male, Middle Aged, Prospective Studies, Tumor Necrosis Factor-alpha
Abstract

OBJECTIVE: To determine whether systemic inflammation after initiation of HIV-antiretroviral therapy (ART) is associated with the development of diabetes.

RESEARCH DESIGN AND METHODS: We conducted a nested case-control study, comparing 55 previously ART-naive individuals who developed diabetes 48 weeks after ART initiation (case subjects) with 55 individuals who did not develop diabetes during a comparable follow-up (control subjects), matched on baseline BMI and race/ethnicity. Stored plasma samples at treatment initiation (week 0) and 1 year later (week 48) were assayed for levels of high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and the soluble receptors of tumor necrosis factor-α (sTNFR1 and sTNFR2).

RESULTS: Case subjects were older than control subjects (median age 41 vs. 37 years, P = 0.001), but the groups were otherwise comparable. Median levels for all markers, except hs-CRP, decreased from week 0 to week 48. Subjects with higher levels of hs-CRP, sTNFR1, and sTNFR2 at 48 weeks had an increased odds of subsequent diabetes, after adjustment for baseline marker level, age, BMI at week 48, CD4 count at week 48 (< vs. >200 cells/mm(3)), and indinavir use (all P(trend) ≤ 0.05). After further adjustment for week 48 glucose, effects were attenuated and only sTNFR1 remained significant (odds ratio, highest quartile vs. lowest 23.2 [95% CI 1.28-423], P = 0.03).

CONCLUSIONS: Inflammatory markers 48 weeks after ART initiation were associated with increased risk of diabetes. These findings suggest that systemic inflammation may contribute to diabetes pathogenesis among HIV-infected patients.

DOI10.2337/dc10-0633
Alternate JournalDiabetes Care
PubMed ID20664016
PubMed Central IDPMC2945167
Grant List5K23-AT-2862 / AT / NCCIH NIH HHS / United States
5UL1-RR-025005 / RR / NCRR NIH HHS / United States
AI-068634 / AI / NIAID NIH HHS / United States
AI-069501 / AI / NIAID NIH HHS / United States
U01-AI-068636 / AI / NIAID NIH HHS / United States